Faculty, UW School of Medicine and Public Health

Jacques Galipeau, MD

  • Hematology
Jacques Galipeau, MD


Dr. Jacques Galipeau is a board-certified hematologist with UW Health, where he treats patients with blood clotting conditions and other blood disorders, such as anemia and blood count abnormalities. He is also a professor at the University of Wisconsin School of Medicine Public Health, Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, where he serves as the associate dean for therapeutic development and the director of the Advanced Cell Therapy Program.

Dr. Galipeau entered medicine to make a difference in people’s lives by using science and its innovations to cure patients. His philosophy is to provide the best care suitable for each patient’s needs. He also has a clinical interest in telemedicine.

He is an international expert in developing cell therapies for catastrophic illnesses like cancers and immune diseases. Dr. Galipeau’s research focuses on creating personalized cell therapies to treat these disorders.

In his free time, Dr. Galipeau enjoys using locally sourced ingredients for slow cooking at home and rescuing dogs.

Languages spoken
  • English
University affiliation

Practice locations

    Education & credentials

    Board certifications
    • Hematology
    Medical School
    • Universite de Montreal, Montreal, Quebec, Canada

    Hematology and Oncology, Tufts Medical Center, New England Medical Center Hospital, Boston, MA

    • Jewish General Hospital, Montreal, Quebec, Canada
    • Universite de Montreal, Montreal, Quebec, Canada

    Research and publications

    Dr. Galipeau is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin-Madison, and the inaugural Assistant Dean for Therapeutics Discovery and Development at the UW School of Medicine and Public Health. Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally-recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous, marrow-derived mesenchymal stromal cells for immune disorders, including Crohn's disease and graft versus host disease. He has also developed the field of fusion engineered cytokines, known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is the director of the University of Wisconsin Advanced Cell Therapy Program, whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of cell therapy innovations to improve outcomes for children and adults.